Related Experiment Video
Updated: Jun 18, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Targeting treatment using calculated cardiovascular disease risk: effective? A shot in the dark? Or is it time to
1Clinical Chemistry Department, Queen's Hospital, Burton-on-Trent, UK. tim.reynolds@burtonhtr.wmids.nhs.uk
Background:
The current paradigm for cardiovascular risk screening is one of screen and treat; i.e. a risk calculation is used to screen the population to determine who should receive therapy. This is marginally effective with somewhere between 199 and 999 people receiving lipid-lowering therapy and consequently being exposed to the drug-related risk without receiving any benefit.
Hypothesis:
New evidence suggests that a diagnostic test could be applied to decide which patients will benefit from treatment.
Conclusion:
Changing the paradigm from 'screen and treat' to 'screen, diagnose and treat' could save large amounts of money by avoiding drugs and could prevent many people from being exposed to side effects.
Insights
The current cardiovascular screening approach is inefficient. A new diagnostic test could improve patient outcomes by identifying who truly benefits from treatment, saving costs and preventing side effects.
Area of Science:
- Cardiology
- Medical Diagnostics
- Health Economics
Background:
- Current cardiovascular risk screening uses a 'screen and treat' model.
- This approach is often ineffective, leading to unnecessary treatments and associated risks for many individuals.
Purpose of the Study:
- To evaluate a new diagnostic test for cardiovascular disease.
- To determine if this test can identify patients who will benefit from specific treatments.
Main Methods:
- The study proposes a shift in screening methodology.
- Implementation of a diagnostic test prior to treatment initiation.
Main Results:
- The current 'screen and treat' strategy results in significant numbers of people receiving therapies without benefit.
- This leads to unnecessary exposure to drug-related risks.
Conclusions:
- Transitioning to a 'screen, diagnose, and treat' paradigm is recommended.
- This change has the potential to reduce healthcare costs by avoiding unnecessary drug prescriptions.
- It can also prevent adverse drug reactions in patients who do not benefit from treatment.
Related Concept Videos
Atherosclerosis III: Management
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenomics: Identification of New Drug Targets
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...